Contents 3 min read

Claim and source comparison

Abstracts of two controlled human experiments and one narrative review, drug labels and the relevant PKU-guideline section were read. Randomization was not verified in abstracts; the controlled-trial label does not assert nonrandomization. Not a full clinical review.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Human controlled trial; randomization not verified

Shurtleff et al. (1994) examined working memory in the cold in 8 male volunteers using 150 mg/kg L-tyrosine and found benefit on one task measure. This small experiment does not validate a standard 500–2000 mg dose for healthy people or benefit under all stress conditions.

Limited to eight men and one cold-task protocol; no task effect was seen at 22 °C. The 150 mg/kg research amount cannot become a standard daily dose. The accessed abstract did not verify randomization, so no RCT label was assigned.

Source 1 · Abstract read

Human controlled trial; randomization not verified

Neri et al. (1995) compared a split 150 mg/kg L-tyrosine amount with placebo under double blinding during one night of sleep loss. Benefits on selected psychomotor and vigilance tasks lasted approximately three hours.

A three-hour task difference is not plasma half-life, a sleep substitute or personal timing. The accessed abstract does not verify randomization; this experiment does not establish everyday performance, effects under all stressors or long-term safety.

Source 2 · Abstract read

Narrative review

The Jongkees et al. (2015) narrative review describes variable L-tyrosine findings and possible benefits related to short-term stress or cognitive demands. Potential for clinical disease treatment and physical exercise was judged more limited.

This is a narrative review, not a pooled-effect meta-analysis or oral comparison with NALT. Being a biochemical precursor does not guarantee increased dopamine or clinical benefit for everyone.

Source 4 · Abstract read

Official safety summary

The phenelzine label explicitly lists L-tyrosine among substances that should not be taken together, with a hypertensive-crisis warning. The carbidopa/levodopa label describes competition with certain amino acids for intestinal transport and reduced absorption with high-protein diets.

These labels concern the named medicines, not equal evidence for every MAOI, supplement dose or NALT. Do not change prescribed medication; review combined use with a doctor or pharmacist. This information does not generate personal medication times.

Source 6 · Source 7 · Official summary read

Our evidence and source methodology

L-Tyrosine: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is L-Tyrosine?

L-Tyrosine is an amino acid used in catecholamine synthesis. Small, variable human experiments studied selected tasks under stress; they do not establish general cognitive enhancement, a personal dose or equivalence with NALT.

Clinical Evidence

Shurtleff et al. (1994) examined working memory in the cold in 8 male volunteers using 150 mg/kg L-tyrosine and found benefit on one task measure. This small experiment does not validate a standard 500–2000 mg dose for healthy people or benefit under all stress conditions.

Limited to eight men and one cold-task protocol; no task effect was seen at 22 °C. The 150 mg/kg research amount cannot become a standard daily dose. The accessed abstract did not verify randomization, so no RCT label was assigned.

Neri et al. (1995) compared a split 150 mg/kg L-tyrosine amount with placebo under double blinding during one night of sleep loss. Benefits on selected psychomotor and vigilance tasks lasted approximately three hours.

A three-hour task difference is not plasma half-life, a sleep substitute or personal timing. The accessed abstract does not verify randomization; this experiment does not establish everyday performance, effects under all stressors or long-term safety.

The Jongkees et al. (2015) narrative review describes variable L-tyrosine findings and possible benefits related to short-term stress or cognitive demands. Potential for clinical disease treatment and physical exercise was judged more limited.

This is a narrative review, not a pooled-effect meta-analysis or oral comparison with NALT. Being a biochemical precursor does not guarantee increased dopamine or clinical benefit for everyone.

L-Tyrosine vs N-Acetyl-L-Tyrosine (NALT)

The Jongkees et al. (2015) review concerns L-tyrosine supplementation. The abstract read does not establish oral NALT cognitive superiority, faster effects or use at the same dose as L-tyrosine.

A parent-compound experiment cannot automatically establish clinical efficacy of its acetylated derivative. This limited reading does not claim all NALT research is absent; distinguish a research question from a demonstrated result.

Dose information and research limits

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

Safety and Side Effects

The phenelzine label explicitly lists L-tyrosine among substances that should not be taken together, with a hypertensive-crisis warning. The carbidopa/levodopa label describes competition with certain amino acids for intestinal transport and reduced absorption with high-protein diets.

These labels concern the named medicines, not equal evidence for every MAOI, supplement dose or NALT. Do not change prescribed medication; review combined use with a doctor or pharmacist. This information does not generate personal medication times.

Tyrosine is not prohibited in PKU; reduced production from phenylalanine can make it part of specialist-managed nutrition. Do not self-adjust extra tyrosine doses; it does not replace standard PKU treatment.

Related research and reading

These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.

Educational guides

Sources

  1. Shurtleff D, et al. (1994). Tyrosine reverses a cold-induced working memory deficit in humans. Pharmacology Biochemistry and Behavior, 47(4), 935–941. PubMed · PMID 8029265
  2. Neri DF, et al. (1995). The effects of tyrosine on cognitive performance during extended wakefulness. Aviation, Space, and Environmental Medicine, 66(4), 313–319. PubMed · PMID 7794222
  3. Deijen JB, Orlebeke JF. (1994). Effect of tyrosine on cognitive function and blood pressure under stress. Brain Research Bulletin, 33(3), 319–323. PubMed · PMID 8293316
  4. Jongkees BJ, et al. (2015). Effect of tyrosine supplementation on clinical and healthy populations under stress or cognitive demands--A review. Journal of Psychiatric Research, 70, 50–57. PubMed · PMID 26424423
  5. van Wegberg AMJ, et al. (2017). The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet Journal of Rare Diseases, 12(1), 162. https://doi.org/10.1186/s13023-017-0685-2 PubMed · PMID 29025426
  6. DailyMed. Phenelzine sulfate: US prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa041652-fdde-4794-a8d2-279dd309e075 DailyMed / US National Library of Medicine
  7. DailyMed. Carbidopa and levodopa: US prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f6d393e-ac84-4a3c-a837-199d1ec71fd2 DailyMed / US National Library of Medicine

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions